Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | TK1 | P04183 | 3/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | TK2 | O00142 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982483 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL4115443 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL11052655 | 0.91 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL10400312 | 0.91 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5982682 | 0.91 | TK1 (0.70) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL10401030 | 0.88 | TK1 (0.71) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL9465344 | 0.88 | TK1 (0.67) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5982148 | 0.88 | TK1 (0.67) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL5983818 | 0.88 | TK1 (0.67) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| SCHEMBL1172396 | 0.88 | TK1 (0.67) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0719271-B1 | 5-(1-FLUORO-VINYL)-1H-PYRIMIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | MERRELL PHARMA INC (US) | 1997-11-26 | — | — | EP | claimed |
| EP-0719271-A1 | 5-(1-FLUORO-VINYL)-1H-PYRIMIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-03 | — | — | EP | claimed |
| US-5512678-A | MAY BE USED IN CONJUNCTION WITH 5-FLUOROURACIL | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-30 | — | — | US | claimed |
| WO-1995007917-A1 | 5-(1-FLUORO-VINYL)-1H-PYRIMIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-23 | — | — | WO | claimed |
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | REPLIDYNE, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | REPLIDYNE, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-0719271-B1 | 5-(1-FLUORO-VINYL)-1H-PYRIMIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | MERRELL PHARMA INC (US) | 1997-11-26 | — | — | EP | disclosed |
| EP-0719271-A1 | 5-(1-FLUORO-VINYL)-1H-PYRIMIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5512678-A | MAY BE USED IN CONJUNCTION WITH 5-FLUOROURACIL | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1995007917-A1 | 5-(1-FLUORO-VINYL)-1H-PYRIMIDINE-2,4-DIONE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | TDO2, TALDO1, NAT1 | LMNA 4826/4885SMN1; SMN2 4796/4885TK1 305/4885 |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | TDO2, TALDO1, NAT1 | LMNA 4826/4885SMN1; SMN2 4796/4885TK1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.